INSTITUT UNIVERSITAIRE
DU CANCER DE TOULOUSE
Oncopole

Les vendredis de l'Oncopole

De la lymphadénopathie angio-immunoblastique au lymphome TFH
30 années de déconvenues et d'espoirs

Animé par **Pr Philippe GAULARD**

Faculté de Médecine, Université Paris-Est Créteil
IMRB – Inserm U955

22 Sept

13h30 – **14**h30

A l'IUCT-Oncopole, salle modulaire 004

SEPTEMBRE,
Mois de sensibilisation aux
CANCERS DU SANG

pour le grand public et les professionnels de santé

Institut Universitaire du cancer Toulouse - Oncopole
1 avenue Irène Joliot-Curie, Toulouse

RÉSUMÉ

Philippe Gaulard, M.D., is Professor of Pathology at the Paris-Est University School of Medicine in Créteil (France), former chair of the Department of Pathology at Henri Mondor Hospital and is the director of the research Unit at the INSERM focusing on the oncogenesis of lymphoid malignancies. He maintains an important practice of hematopathology comprising many consultation cases, chairing the national Lymphopath network to review any newly diagnosed lymphoma in France sponsored by the National Cancer Agency (INCa). He is member of the executive committee of the LYSA (Lymphoma Study Association), a large multicentric consortium of hematologists and pathologists from France and several neighbouring countries conducting clinical trials for the treatment of adult aggressive lymphomas, and is the scientific director of the Institute Carnot CALYM, a national research lymphoma network. He is a member of the International Lymphoma Study Group (ILSG) and was member of the WHO 4th Lymphoma Classification Committee, and, as so, has authored several chapters of the updated (2008 and 201 7) WHO classification of Tumo urs of Haematopoietic and Lymphoid Tissues. In 2022, he was Invited as member of the Clinical Advisory Committee of the International Consensus Conference (ICC) for the classification of lymphoid neoplasms. He has been elected as the President of the European Association for Hematopathology (EAHP) from 2010-12. He received several awards , was invited to give the John Ultmann Memorial Lecture, at the 15-ICML, Lugano, in 2019, and the Karl Lennert lecture, at the 21th Meeting of the EAHP, Florence, in 2022. He has authored more than 420 scientific publications indexed in PubMed. His current research interest includes the molecular characterization of lymphoma entities including primary mediastinal large B-cell lymphoma and neoplasms derived from T and NK cells. In this field, he has described hepatosplenic γδ T-cell lymphomas , now recognized as a distinct clinicopathologic entity, has characterized the molecular signature of HSTL and NK/T-cell lymphomas, nasal-type and identified the normal cell counterpart of angio-immunoblastic T-cell lymphoma. He has recently contributed to the description of the genetic landscape of several lymphoma entities , especially TFH lymphomas, and to the identification of alternative therapeutic targets for T-cell lymphomas.

Institut universitaire du cancer Toulouse - Oncopole
1 avenue Irène Joliot-Curie, Toulouse